IGFBP-6 plays a role as an oncosuppressor gene in NPC pathogenesis through regulating EGR-1 expression

Journal of Pathology

Volumn 222, Issue 3, 2010, Pages 299-309

  Kuo, Yuan Sung ^a,b   Tang, Yueh Bih ^b   Lu, Tung Ying ^a,c   Wu, Han Chung ^a,c   Lin, Chin Tarng ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

Author keywords

EGR 1; IGFBP 6; Nasopharyngeal carcinoma (NPC); Tumour progression

Indexed keywords

COMPLEMENTARY DNA; EARLY GROWTH RESPONSE FACTOR 1; LUCIFERASE; SOMATOMEDIN BINDING PROTEIN 6; TUMOR PROTEIN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INVASION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA MICROARRAY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION; ANIMAL; BIOPSY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; PROCEDURES; PROMOTER REGION; SCID MOUSE; SUPPRESSOR GENE; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; BIOPSY; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, SUPPRESSOR; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 6; MICE; MICE, SCID; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 77958005058     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2735     Document Type: Article

References (47)

1. Shanmugaratnam K. Histological Typing of Tumours of the Upper Respiratory Tract and Ear, 2nd edn. Springer-Verlag: New York, 1991.
2. Waterhouse L, Muir C, Shanmugaratnam K, et al. Cancer Incidence in Five Countries. International Agency for Research on Cancer: Lyon, 1982.
3. Department of Health, Executive Yuan Republic of China (Taiwan), 2007.
4. Jia WH, Collins A, Zeng YX, et al. Complex segregation analysis of nasopharyngeal carcinoma in Guangdong, China: evidence for a multifactorial mode of inheritance (complex segregation analysis of NPC in China). Eur J Hum Genet 2005;13:248-252.
5. Yu MC, Nichiks PW, Zou XN, et al. Induction of nasal cavity tumor in Wistar rats fed Chinese salted fish. Br J Cancer 1989;60:198-201.
6. Ho CK, Lo W C H, Huang PH, et al. Suspected nasopharyngeal carcinoma in three workers with long-term exposure to sulphuric acid vapour. Occup Environ Med 1999;56:426-428.
7. zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970;228:1056-1058.
8. Zeng Y, Zhang LG, Li HY, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 1982;29:139-141.
9. Niedobitek G, Young LS, Sam CK, et al. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferential nasopharyngeal carcinoma. Am J Pathol 1992;140:879-887.
10. Wu HC, Lin JY, Lee JJ, et al. Functional analysis of EBV in nasopharyngeal carcinoma cells. Lab Invest 2003;83:797-812.
11. Wu HC, Lu TY, Lee JJ, et al. MDM2 expression in EBV-infected nasopharyngeal carcinoma cells. Lab Invest 2004;84:1547-1556.
12. Lin CT. Epstein-Barr virus: new research in epithelial carcinoma. In New Developments in EBV Research, Ulmar CS (ed.). Nova Science: New York, 2004;71-91.
13. Shi W, Bastianutto C, Li A, et al. Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int J Cancer 2006;119:2467-2475.
14. Zeng ZY, Zhou YH, Zhang WL, et al. Gene expression profiling of nasopharyngeal carcinoma reveals the abnomally regulated Wnt signaling pathway. Hum Pathol 2007;38:120-133.
15. Chow LS, Lam CW, Chan SY, et al. Identification of RASSF1A modulated genes in nasopharyngeal carcinoma. Oncogen 2006;25:310-316.
16. Lin CT, Wong CI, Chan WY, et al. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest 1990;62:713-724.
17. Lin CT, Chan WY, Chen W, et al. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 1993;68:716-727.
18. Lee Y C G, Hwang YC, Chen KC, et al. Effect of Epstein-Barr virus infection on global gene expression in nasopharyngeal carcinoma. Funct Integr Genom 2007;7:79-93.
19. Plymate SR, Tennant M, Bringaum RS, et al. The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metab 1996;81:3709-3716.
20. Ilvesmäki S, Liu J, Heikkilä P, et al. Expression of insulin-like growth factor binding protein 1-6 genes in adrenocortical tumors and pheochromocytomas. Horm Metab Res 1998;30:619-623.
21. Ueoka N, Lee HY, Wiehle S, et al. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogen 2000;19: S4432-4436.
22. Grellier P, Berrebi D, Bsbajko S. The IGF system in neuroblastoma xenografts: focus on IGF-binding protein-6. J Endocrinol 2002;17:467-476.
23. Oh Y, Nagalla SR, Yamanaka Y. Synthesis and characterization of insulin-like growth factor binding protein-7 (IGFBP-7). J Biol Chem 1996;271:30322-30325.
24. Martin JL, Willetts KE, Baxter RC. Purification and properties of a novel insulin-like growth factor-II binding protein from transformed human fibroblasts. J Biol Chem 1990;265:4124-4130.
25. Bach LA, Hsieh S, Sakano K, et al. Bindings of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. J Biol Chem 1993;268:9246-9254.
26. Leng SL, Leeding KS, Whitehead RH, et al. Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. Mol Cell Endocrinol 2001;174:121-127.
27. Huang DY, Lin YT, Jan PS, et al. Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by downregulating SPARC gene expression. J Pathol 2008;214:445-455.
28. Wu HC, Huang PH, Chiu CY, et al. G protein β-subunit antisense oligonucleotides inhibit cell proliferation and disorganize microtubule and mitotic spindle organization. J Cell Biochem 2001;83:136-146.
29. Bargou RC, Wagener C, Bommert K, et al. Blocking of transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID Mice. J Exp Med 1996;183:1205-1211.
30. Yu J, Zhang SS, Saito K, et al. PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J 2009;28:21-33.
31. Zagurovskaya M, Shareef MM, Das A, et al. EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene 2009;28:1121-1131.
32. Hwang YC, Lu TY, Huang DY, et al. NOLC1, an enhancer of nasopharyngeal carcinoma progression, is essential for TP53 to regulate MDM2 expression. Am J Pathol 2009;175:342-345.
33. Baron V, Adamson ED, Calogero A, et al. The transcription factor Egr-1 is a direct regulator of multiple tumor suppressors, including TGFβ1, PTEN, p53 and fibronectin. Egr1 is a potential target of gene therapy for prostate cancer. Cancer Gene Ther 2006;13:115-124.
34. Grellier P, De Galle B, Babajko S. Expression of insulin-like growth factor-binding protein 6 complementary DNA alters neuroblastoma cell growth. Cancer Res 1998;58:1670-1676.
35. Bach LA. IGFBP-6 five years on; not so forgotten? Growth Horm IGF Res 2005;15:185-192.
36. Koyama N, Zhang J, Huqun, et al. Identification of IGFBP-6 as an effector of the tumour suppressor activity of SEMA3B. Oncogene 2008;27:6581-6589.
37. Sueoka N, Lee HY, Wiehle S, et al. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 2000;19:4432-4436.
38. Koike H, Ito K, Takezawa Y, et al. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer. Br J Cancer 2005;92:1538-1544.
39. Gallicchio MA, Kneen M, Hall C, et al. Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int J Cancer 2001;94:645-657.
40. Liu C, Calogero A, Ragona G, et al. EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGFβ1 is postulated to account for this suppressor activity. Crit Rev Oncog 1996;7:101-125.
41. Adamson ED, Mercola D. Egr1 Transcription factor: multiple roles in prostate tumour cell growth and survival. Tumor Biol 2002;23:93-102.
42. Yu J, Zhang SS, Saito K, et al. PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J 2009;28:21-33.
43. Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor-β1. Proc Natl Acad Sci USA 1996;15:11831-11836.
44. Baek SJ, Kim JS, Moore SM, et al. Cyclooxygenase inhibitors induce the expression of the tumour suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005;67:356-364.
45. Liu C, Rangnekar VM, Adamson E, et al. Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther 1998;5:3-28.
46. Calogero A, Lombari V, De Gregorio G, et al. Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int 2004;4:1.
47. Huang RP, Fan Y, de Belle I, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumour formation. Int J Cancer 1997;72:102-109.